QIAGEN Reportedly Secures FDA Clearance for Bloodstream Infection Panel

QIAGEN has secured FDA clearance for a rapid bloodstream infection panel, according to Openpr. The report presents the regulatory development in the context of the U.S. sepsis diagnostic market.

FDA clearance reported by Openpr

Openpr identifies QIAGEN as the company associated with the reported FDA clearance and describes the product as a rapid bloodstream infection panel. The published headline characterizes the development as an expansion in the U.S. sepsis diagnostic market.

The available evidence does not provide further product-specific details. It does not describe assay targets, workflow, instrument compatibility, clinical performance, intended-use language, or the timing of the FDA action beyond Openpr’s publication date.

For medical diagnostics and laboratory sales professionals, the central development is the reported clearance of a rapid bloodstream infection panel. Customer discussions should distinguish the reported regulatory event from product specifications that are not included in the available Openpr summary.

Sepsis diagnostics market context

Openpr cites DataM Intelligence on the global sepsis diagnostic market. According to the figures included in the report, the market reached US 0 88 billion in 2026 and is projected to reach US 1 4 billion by 2031.

The report states a CAGR of 9 5 during 2026 2031. These figures provide market context for the reported QIAGEN regulatory development, while the clearance itself concerns a rapid bloodstream infection panel in the U.S. sepsis diagnostics market.

Points established in the available report

• Openpr reports FDA clearance for a QIAGEN rapid bloodstream infection panel.
• Openpr places the development within the U.S. sepsis diagnostic market.
• Openpr cites DataM Intelligence figures for the global sepsis diagnostic market.
• The supplied report does not provide additional assay, performance, workflow, or intended-use details.

The event is relevant to professionals following bloodstream infection testing and sepsis diagnostics. As described by Openpr, it combines a reported FDA clearance with a market report that cites projected growth in global sepsis diagnostics through 2031.